MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
30.54
-2.43 (-7.37%)
At close: Mar 3, 2026, 4:00 PM EST
31.31
+0.77 (2.52%)
Pre-market: Mar 4, 2026, 8:27 AM EST
MBX Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for MBX Biosciences stock have an average target of 54.2, with a low estimate of 18 and a high estimate of 88. The average target predicts an increase of 77.47% from the current stock price of 30.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 28, 2026.
Analyst Ratings
The average analyst rating for MBX Biosciences stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 5 | 6 | 6 |
| Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 8 | 6 | 7 | 9 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $66 | Buy | Initiates | $66 | +116.11% | Jan 28, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $77 → $88 | Strong Buy | Maintains | $77 → $88 | +188.15% | Jan 16, 2026 |
| UBS | UBS | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +96.46% | Jan 7, 2026 |
| Stifel | Stifel | Strong Buy Maintains $45 → $50 | Strong Buy | Maintains | $45 → $50 | +63.72% | Dec 19, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Initiates $18 | Strong Sell | Initiates | $18 | -41.06% | Dec 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.52
from -5.82
EPS Next Year
-3.02
from -2.52
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.31 | -2.17 | ||||
| Avg | -2.52 | -3.02 | ||||
| Low | -2.76 | -4.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.